All In Biotech

Drug Trial Radar · NCT04115319

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 305 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

305

Actual

Start

Nov 21, 2019

Primary completion

Dec 30, 2022

Study completion Dec 30, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.

Conditions

  • Schizophrenia

Interventions

  • SEP363856Drug

    SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule

  • quetiapine XRDrug

    quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study DiscontinuationTime frame: From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks)

Locations

42 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Cerritos, California

  • Research Site

    Oakland, California

  • Research Site

    Oceanside, California

  • Research Site

    San Diego, California

  • Research Site

    Torrance, California

  • Research Site

    Miami, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Hoffman Estates, Illinois

  • Research Site

    Lincolnwood, Illinois

  • Research Site

    Shreveport, Louisiana

  • Research Site

    St Louis, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Cedarhurst, New York

  • Research Site

    Jamaica, New York

  • Research Site

    Rochester, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    North Canton, Ohio

  • Research Site

    Brasov, Romania

  • Research Site

    Bucharest, Romania

  • Research Site

    Bucharest, Romania

  • Research Site

    Bucharest, Romania

  • Research Site

    Iași, Romania

  • Research Site

    Arkhangelsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Smolensk, Russia

  • Research Site

    Stavropol, Russia

  • Research Site

    Tomsk, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

  • Research Site

    Ivano-Frankivsk, Ukraine

  • Research Site

    Kharkiv, Ukraine

  • Research Site

    Kyiv, Ukraine

  • Research Site

    Smila, Ukraine

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.